Differential effects of cyclosporin A on diverse B cell activation phenomena triggered by crosslinking of membrane IgM.
Cyclosporin A (CsA) was tested for its modulatory effects on the mIgM-mediated signaling of G0*-associated increases in class II MHC expression, G1-related RNA synthesis, and S phase-related DNA synthesis in human B cells. While CsA at concentrations as low as 10-100 ng/ml could completely ablate anti-IgM-induced DNA synthesis, earlier G1-associated RNA synthesis was only partially inhibited, and signaling of increased membrane class II MHC expression was unaffected by up to 1000 ng/ml of CsA. Similar phenomena were observed in a clonal population of leukemic B lymphocytes susceptible to anti-IgM-mediated activation in the absence of T cells and T cell factors indicating (a) that the inhibitory effects are not due to CsA-mediated suppression of cytokine production by contaminating T cells, and (b) that the varying effects of CsA on the diverse activation phenomena do not reflect B cell subpopulation diversity. Pulsing studies revealed that while maximal suppression of anti-IgM-induced G1-associated RNA synthesis required CsA at culture initiation, near maximal suppression of DNA synthesis occurred when CsA, or soluble human IgM, was added up to 30 hr after the initial exposure of resting B cells to the anti-IgM ligand. These latter findings are consistent with the possibility that the CsA-mediated suppression of S phase entry is due to the inhibition of a signaling event proximal to mIgM ligation which must be repeatedly initiated throughout the first 30 hr of activation.
Department of Rheumatic Diseases, Hospital for Joint Diseases, New York, New York 10003.
P K
PK
Mongini
C A
CA
Blessinger
J P
JP
Dalton
T
T
Seki
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D015152:Blotting, Northern; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000494:pharmacology*; D016207:Cytokines / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D005434:Flow Cytometry; D006683:HLA-DQ Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D012313:RNA / Q000096:biosynthesis; D011961:Receptors, Fc / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000888:Antibodies, Anti-Idiotypic; D016207:Cytokines; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D007075:Immunoglobulin M; D011961:Receptors, Fc; C035311:immunoglobulin M receptor; D012313:RNA; D016572:Cyclosporine; D004247:DNA